Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist

John D. Baxter, Patrick Goede, James W. Apriletti, Brian L. West, Weijun Feng, Karin Mellstrom, Robert J. Fletterick, Richard L. Wagner, Peter J. Kushner, Ralff C J Ribeiro, Paul Webb, Thomas (Tom) Scanlan, Stefan Nilsson

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Antagonists have been developed for several nuclear receptors but not for others, including TRs. TR antagonists may have significant clinical utility for treating hormone excess states and other conditions. A structure derived "extension hypothesis" was applied to synthesize a TR antagonist. The principal design feature was to attach an extension group to a TR agonist whose structure would perturb formation of the TR coactivator-binding surface. The compound, 3,5-dibromo-4-(3′,5′-diisopropyl-4′-hydroxyphenoxy)benzoic acid, has no (TRα) or very weak partial (TRβ) TR agonist activity and blocks TR binding of T3, formation of the coactivator-binding surface, and both a positive T3 response on a thyroid hormone response element and a negative T3 response on the TSHβ promoter in cultured cells. The results suggest that 3,5-dibromo-4-(3′,5′-diisopropyl-4′-hydroxyphenoxy)benzoic acid is a TR antagonist for thyroid hormone response element-mediated responses, this approach can be used more generally to generate nuclear receptor antagonists, and this compound or analogues may have medical and research utility.

Original languageEnglish (US)
Pages (from-to)517-524
Number of pages8
JournalEndocrinology
Volume143
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Hormone Antagonists
Thyroid Hormone Receptors
Benzoic Acid
Response Elements
Hormones
Cytoplasmic and Nuclear Receptors
Thyroid Hormones
Biomedical Research
Cultured Cells

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Baxter, J. D., Goede, P., Apriletti, J. W., West, B. L., Feng, W., Mellstrom, K., ... Nilsson, S. (2002). Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology, 143(2), 517-524. https://doi.org/10.1210/en.143.2.517

Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. / Baxter, John D.; Goede, Patrick; Apriletti, James W.; West, Brian L.; Feng, Weijun; Mellstrom, Karin; Fletterick, Robert J.; Wagner, Richard L.; Kushner, Peter J.; Ribeiro, Ralff C J; Webb, Paul; Scanlan, Thomas (Tom); Nilsson, Stefan.

In: Endocrinology, Vol. 143, No. 2, 2002, p. 517-524.

Research output: Contribution to journalArticle

Baxter, JD, Goede, P, Apriletti, JW, West, BL, Feng, W, Mellstrom, K, Fletterick, RJ, Wagner, RL, Kushner, PJ, Ribeiro, RCJ, Webb, P, Scanlan, TT & Nilsson, S 2002, 'Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist', Endocrinology, vol. 143, no. 2, pp. 517-524. https://doi.org/10.1210/en.143.2.517
Baxter JD, Goede P, Apriletti JW, West BL, Feng W, Mellstrom K et al. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology. 2002;143(2):517-524. https://doi.org/10.1210/en.143.2.517
Baxter, John D. ; Goede, Patrick ; Apriletti, James W. ; West, Brian L. ; Feng, Weijun ; Mellstrom, Karin ; Fletterick, Robert J. ; Wagner, Richard L. ; Kushner, Peter J. ; Ribeiro, Ralff C J ; Webb, Paul ; Scanlan, Thomas (Tom) ; Nilsson, Stefan. / Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. In: Endocrinology. 2002 ; Vol. 143, No. 2. pp. 517-524.
@article{a3c4a88eeb48449098e8c9ffc34f57e3,
title = "Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist",
abstract = "Antagonists have been developed for several nuclear receptors but not for others, including TRs. TR antagonists may have significant clinical utility for treating hormone excess states and other conditions. A structure derived {"}extension hypothesis{"} was applied to synthesize a TR antagonist. The principal design feature was to attach an extension group to a TR agonist whose structure would perturb formation of the TR coactivator-binding surface. The compound, 3,5-dibromo-4-(3′,5′-diisopropyl-4′-hydroxyphenoxy)benzoic acid, has no (TRα) or very weak partial (TRβ) TR agonist activity and blocks TR binding of T3, formation of the coactivator-binding surface, and both a positive T3 response on a thyroid hormone response element and a negative T3 response on the TSHβ promoter in cultured cells. The results suggest that 3,5-dibromo-4-(3′,5′-diisopropyl-4′-hydroxyphenoxy)benzoic acid is a TR antagonist for thyroid hormone response element-mediated responses, this approach can be used more generally to generate nuclear receptor antagonists, and this compound or analogues may have medical and research utility.",
author = "Baxter, {John D.} and Patrick Goede and Apriletti, {James W.} and West, {Brian L.} and Weijun Feng and Karin Mellstrom and Fletterick, {Robert J.} and Wagner, {Richard L.} and Kushner, {Peter J.} and Ribeiro, {Ralff C J} and Paul Webb and Scanlan, {Thomas (Tom)} and Stefan Nilsson",
year = "2002",
doi = "10.1210/en.143.2.517",
language = "English (US)",
volume = "143",
pages = "517--524",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist

AU - Baxter, John D.

AU - Goede, Patrick

AU - Apriletti, James W.

AU - West, Brian L.

AU - Feng, Weijun

AU - Mellstrom, Karin

AU - Fletterick, Robert J.

AU - Wagner, Richard L.

AU - Kushner, Peter J.

AU - Ribeiro, Ralff C J

AU - Webb, Paul

AU - Scanlan, Thomas (Tom)

AU - Nilsson, Stefan

PY - 2002

Y1 - 2002

N2 - Antagonists have been developed for several nuclear receptors but not for others, including TRs. TR antagonists may have significant clinical utility for treating hormone excess states and other conditions. A structure derived "extension hypothesis" was applied to synthesize a TR antagonist. The principal design feature was to attach an extension group to a TR agonist whose structure would perturb formation of the TR coactivator-binding surface. The compound, 3,5-dibromo-4-(3′,5′-diisopropyl-4′-hydroxyphenoxy)benzoic acid, has no (TRα) or very weak partial (TRβ) TR agonist activity and blocks TR binding of T3, formation of the coactivator-binding surface, and both a positive T3 response on a thyroid hormone response element and a negative T3 response on the TSHβ promoter in cultured cells. The results suggest that 3,5-dibromo-4-(3′,5′-diisopropyl-4′-hydroxyphenoxy)benzoic acid is a TR antagonist for thyroid hormone response element-mediated responses, this approach can be used more generally to generate nuclear receptor antagonists, and this compound or analogues may have medical and research utility.

AB - Antagonists have been developed for several nuclear receptors but not for others, including TRs. TR antagonists may have significant clinical utility for treating hormone excess states and other conditions. A structure derived "extension hypothesis" was applied to synthesize a TR antagonist. The principal design feature was to attach an extension group to a TR agonist whose structure would perturb formation of the TR coactivator-binding surface. The compound, 3,5-dibromo-4-(3′,5′-diisopropyl-4′-hydroxyphenoxy)benzoic acid, has no (TRα) or very weak partial (TRβ) TR agonist activity and blocks TR binding of T3, formation of the coactivator-binding surface, and both a positive T3 response on a thyroid hormone response element and a negative T3 response on the TSHβ promoter in cultured cells. The results suggest that 3,5-dibromo-4-(3′,5′-diisopropyl-4′-hydroxyphenoxy)benzoic acid is a TR antagonist for thyroid hormone response element-mediated responses, this approach can be used more generally to generate nuclear receptor antagonists, and this compound or analogues may have medical and research utility.

UR - http://www.scopus.com/inward/record.url?scp=18244364644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244364644&partnerID=8YFLogxK

U2 - 10.1210/en.143.2.517

DO - 10.1210/en.143.2.517

M3 - Article

C2 - 11796506

AN - SCOPUS:18244364644

VL - 143

SP - 517

EP - 524

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 2

ER -